Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8186 and Docetaxel in PTEN or PIK3CB Mutated Advanced Solid Tumors
NCT03218826Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2018
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azd8186 in solid tumor, breast cancer and prostate cancer (PCa), sponsored by National Cancer Institute. Primary endpoints: Dose Limiting Toxicity at 22 days and Adverse Events Grades 3-5 up to 3 years. Started Sep 2018; status: completed.
02
Drugs
azd8186
03
Conditions
solid tumorbreast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT03218826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03218826.